Clinical & Translational Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2020-02-18 贵族贝勒爷

请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表:
请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？

红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？

110 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-12-22 198366_2801 来自河南省

请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈

40 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-11-11 ms5000000532436837

投稿时需要所以作者邮箱点链接确认身份吗

40 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-08-22 ms2000000713462597

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：胃癌;生信;预后标志物
经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。

35 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-06-07 ms8000000784741196

偏重的研究方向：乳腺癌;内分泌治疗
经验分享：三天了还在new submission，大概要多久啊

27 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-03-20 ms4000001175598795

请问下大家这个杂志格式要求很严格吗

31 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-12-28 ms6000000264964247

讨论中第一段一定要撰写文章的总括么？

48 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-12-29 Mia

模式图一般放在讨论中展示还是放在结果部分？

47 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2016-05-14 1dec8fb5m12(暂无匿称)

刚投一篇回顾性临床研究文章，希望能被接收，祈祷！

323 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=584926, encodeId=68475849265e, content=请问你的这个状态什么时候变化的？红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, beContent=红土之王 2019-07-21 00:00:00 发表: 请问你的editor invited 状态变化了吗？我的7.14号投的，16号是editor invited ，都6天了还是editor invited 状态？不知道要持续多久？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/18/230b48385b8eb41094f5b0a1ca222061.jpg, createdBy=2d305265980, createdName=贵族贝勒爷, createdTime=Tue Feb 18 00:00:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2107057, encodeId=a6a5210e05741, content=请问这个需要通讯作者邮箱点确认吗？不点就提交不了吗？谢谢各位前辈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Thu Dec 22 13:56:27 CST 2022, time=2022-12-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2099794, encodeId=7bbb2099e94d0, content=投稿时需要所以作者邮箱点链接确认身份吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78895723694, createdName=ms5000000532436837, createdTime=Fri Nov 11 08:22:53 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-08-16 ms9000000537367142

偏重的研究方向：肿瘤
经验分享：一天秒拒无理由

59 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务